An update of the leukotriene modulators for the treatment of asthma

Expert Opinion on Investigational Drugs

Volumn 13, Issue 7, 2004, Pages 763-776

  Riccioni, Graziano ^a   Di Ilio, Carmine ^a   D'Orazio, Nicolantonio ^a  

^a UNIVERSITY OF CHIETI   (Italy)

Author keywords

Asthma; Bronchial hyper responsiveness; Compliance; Leukotriene; Leukotriene receptor antagonist; Montelukast; Pranlukast; Quality of life; Zafirlukast; Zileuton

Indexed keywords

ACETYLSALICYLIC ACID; ALZAIRE; ANTIHISTAMINIC AGENT; ANTIINFLAMMATORY AGENT; AZELASTINE; BECLOMETASONE; BETA 2 ADRENERGIC RECEPTOR STIMULATING AGENT; CETIRIZINE; CORTICOSTEROID; CORTICOTROPIN; HYDROCORTISONE; LEUKOTRIENE RECEPTOR BLOCKING AGENT; LONG ACTING DRUG; MONTELUKAST; NONSTEROID ANTIINFLAMMATORY AGENT; PLACEBO; PRANLUKAST; SALMETEROL; SHORT ACTING DRUG; THEOPHYLLINE; THEOPHYLLINE DERIVATIVE; WARFARIN; ZAFIRLUKAST; ZILEUTON;

ABDOMINAL PAIN; ADRENAL SUPPRESSION; AIRWAY OBSTRUCTION; ALLERGIC DISEASE; ALLERGIC RHINITIS; ASTHENIA; ASTHMA; ATOPIC DERMATITIS; CATARACTOGENESIS; CHRONIC INFLAMMATION; CHRONIC URTICARIA; CHURG STRAUSS SYNDROME; CLINICAL PRACTICE; CLINICAL TRIAL; CORTICOSTEROID INDUCED OSTEOPOROSIS; COUGHING; DIARRHEA; DISEASE EXACERBATION; DISEASE PREDISPOSITION; DRUG ABSORPTION; DRUG EFFICACY; DRUG INDICATION; DRUG MECHANISM; DRUG POTENTIATION; DYSPEPSIA; DYSPHONIA; ENVIRONMENTAL EXPOSURE; EVIDENCE BASED MEDICINE; EXERCISE INDUCED ASTHMA; FLUSHING; GASTROINTESTINAL DISEASE; GLAUCOMA; GROWTH DISORDER; HEADACHE; HOARSENESS; HUMAN; INFECTION; INFLUENZA; LARYNGITIS; LIVER TOXICITY; LOW DRUG DOSE; LUNG FUNCTION; METABOLIC DISORDER; MIGRAINE; MYCOSIS; NAUSEA; NEUROENDOCRINE DISEASE; NONHUMAN; OTITIS; PAIN; PARANASAL SINUS DISEASE; PATIENT COMPLIANCE; PATIENT EDUCATION; PATIENT MONITORING; PHARYNGITIS; PRACTICE GUIDELINE; RESPIRATORY TRACT INFLAMMATION; REVIEW; RHINITIS; RHINOSINUSITIS; SIDE EFFECT; SINUSITIS; SKIN MANIFESTATION; TACHYPHYLAXIS; TERATOGENICITY; THROAT DISEASE; THRUSH; VIRUS INFECTION;

ANIMALS; ASTHMA; DRUGS, INVESTIGATIONAL; HUMANS; LEUKOTRIENE ANTAGONISTS;

EID: 3543052301     PISSN: 13543784     EISSN: None     Source Type: Journal    
DOI: 10.1517/13543784.13.7.763     Document Type: Review

References (145)

1. NATIONAL ASTHMA EDUCATION AND PREVENTION PROGRAM: Expert Panel Report 2: guidelines for the diagnosis and management of asthma. NIH Publication No. 97-4051. Bethesda (1997).
2. SAMUELSSON B, DAHLEN SE, LINDGREN JA, ROUZER CA, SERHAN CN: Leukotrienes and lipoxins: structures, biosynthesis, and biological effects. Science. (1987) 237:1171-1176.
3. HOLGATE ST, BRADDING P, SAMPSON AP: Leukotriene antagonists and synthesis inhibitors: new directions in asthma therapy. J. Allergy. Clin. Immunol. (1996)98:1-13.
4. COLEMAN RA, EGLEN RM, JONES RL et al.: Prostanoid and leukotrienes receptors: a progress report from the IUPHAR working parties on classification and nomenclature. Adv. Prost. Thromb. Leuko. Res. (1995) 23:283-285.
5. FORD-HUTCHINSON AW, BRAY MA, DOIG MV, SHIPLEY ME, SMITH MJ: Leukotriene B4, a potent chemokinetic and aggregating substance released from PMN leukocytes. Nature. (1980) 286:264-265.
6. FORD-HUTCHINSON AW: Leukotriene B4 in inflammation. Crit. Res. Immunol. (1990) 10:1-12.
7. PIPER PJ: Formation and actions of leukotrienes. Physiol. Rev. (1984) 64:744-761.
8. LYNCH KR, O'NEILL GP, LIU Q et al.: Characterization of the human cysteinyl leukotriene Cys-LT1 receptor. Naure (1999) 399:789-793.
9. RICCIONI G, SANTILLI F, D'ORAZIO N et al.: The role of antileukotrienes in the treatment of asthma. Int. J. Immunopathol. Pharmacol. (2002) 15:171-182.
10. GLOBAL INITIATIVE FOR ASTHMA: Pocket guide for asthma management and prevention. NIH publicationNo.96-3659B. Bethesda (1998).
11. BRITISH ASTHMA GUIDELINES COORDINATING COMMITTEE: British guidelines on asthma management. 1995 review and position statement. Thorax. (1997) 52:S1-S24.
12. CLARK N, JONES P, KELLER S, VERMEIRE P: Patient factor and compliance with asthma therapy. Pediatr. Pulmonol. (2000) 29:46-61.
13. KELLOWAY JS, WYATT RA, ADLIS SK: Comparison of patienes compliance with prescribed oral and inhaled asthma medication. Arch. Intern. Med. (1994) 154:1349-1352.
14. SPECTOR S: Noncompliance with asthma therapy - are there solutions? J. Asthma. (2000) 37:381-388.
15. BARNES PJ, PEDERSEN S, BUSSE W: Efficacy and safety of inhaled corticosteroids: new development. Am. J. Respir. Crit. Care. Med. (1998) 157:S1-S53.
16. DWORSKI R, FITZGERALD GA, OATES JA, SHELLER JR: Effect of oral prednisone on airway inflammatory mediators in atopic asthma. Am. J. Repir. Crit. Care. Med. (1994) 149:953-959.
17. HOOD PP, COTTER TP, COSTELLO JF, SAMPSON AP: Effect of intravenous corticosteroid on ex vivo leukotriene generation by blood leucocytes of normal and asthmatic patients. Thorax (1999) 54:1075-1082.
18. BOOTH HI, RICHMOND I, WARD C, GARDINER PV, HARKAWAT R, WALTERS EH: Effect of high dose of inhaled fluticasone propionate on airway inflammation in asthma. J. Clin. Endocr. Metab. (1995) 80:1243-1246.
19. BARNES PJ: Efficacy of inhaled corticosteroids in asthma. J. Allergy. Clin. Immunol. (1998) 102:531-538.
20. EL-RADHI AS, HOGG CL, BUNGRE JK, BUSH A, CORRIGAN CJ: Effect of oral glucocorticoid treatment on serum inflammatory markers in acute asthma. Arch. Dis. Child. (2000) 83:158-162.
21. BARNES PJ: Inhaled glucocorticoids for asthma. N. Engl. J. Med. (1995) 332:868-875.
22. VATHEEN AS, KNOX AJ, WISIEWSKI A, TATTERSFIELD AE: Tune course of change in bronchial reactivity with an inhaled corticosteroid in asthma. Am. Rev. Respir. Dis. (1991) 143:1317-1321.
23. BELL EH, TIMMERS MC, HERMANS J, DIJKMAN H, STERK PJ: The long-term effect of nedocromil sodium and beclomethasone dipropionate on bronchial responsiveness to methacholine in nonatopic asthmatic subjects. Am. Rev. Respir. Dis. (1990) 141:21-28.
24. JUNIPER EP, KLINE PA, VANZIELEGHEM MA, RAMSDALE EH, O'BYRNE PM, HARGREAVE PK: Effect of long-term treatment with an inhaled corticosteroid (budesonide) on airway hyperresponsiveness and clinical asthma in nonsteroid-dependent asthmatics. Am. Resper. Rev. Dis. (1990) 142:832-836.
25. DJUKANOVIC P, LAI CK, WILSON JW et al.: Effect of an inhaled corticosteroid on airway inflammation and symptoms in asthma. Am. Rev. Respir. Dis. (1992) 256:669-674.
26. BANOV CH, HOWLAND WC, LUMRY WK: Once-daily budesonide via Turbohaler improves symptoms in adults with persistent asthma. Ann. Allergy. Asthma Immunol. (2001) 86:627-632.
27. BANOV C, HOWLAND WC, LUMRY WR, PARASURAMAN B, URNYAK T, LILJAS B: Budesonide turbohaler delivered once daily improved health-related quality of life in adult patients with non-steroid-dependent asthma. All. Asthma. Proc. (2003) 24:129-136.
28. NIKOLAIZIK WH, MARCHANT JL, PREECE MA, WARNER JO: Endocrine and lung function in asthmatic children on inhaled corticosteroid. Am. J. Respir. Crit. Care. Med. (1994) 150:624-629.
29. WONG CA, WALSH LJ, SMITH CJ et al.: Inhaled corticosteroid use and bone mineral density in patients with asthma. Lancet. (2000) 355:1399-1403.
30. LEONE FT, FISH JE, SZEFLER SJ, WEST SL: Systematic review of the evidence regarding potential complications of inhaled corticosteroid use in asthma: collaboration of American College of Chest Physicians, American Academy of Allergy, Asthma, and Immunology, and American College of Allergy, Asthma, and Immunology. Chest (2003) 124:2329-2340.
31. LIPWORTH PJ, WILSON AM: Dose response to inhaled corticosteroids: benefits and risks. Sem. Resp. Critical. Care. Med. (1998) 19:625-646.
32. DRAZEN JM, ISRAEL E, O'BYRNE PM: Treatment of asthma with drugs modifying leukotriene pathway. N. Engl. J. Med. (1999) 340:197-206.
33. WENZEL SE: Antileukotriene drugs in the management of asthma. JAMA. (1998) 280:2068-2069.
34. SPECTOR SL: Management of asthma with zafirlukast. Clinical experience and tolerability profile. Drugs (1996) 54:369-384.
35. MARKHAM A, FAULDS D: Montelukast. Drugs (1998) 56:251-256.
36. SMITH LJ: A risk-benefit assessment of antileukotrienes in asthma. Drug Saf. (1998) 19:205-218.
37. KNORR B, MATZ J, BERNSTEIN JA: Montelukast for chronic asthma in 6- to 14-year old children. A randomized, double-blind trial. JAMA (1998) 279:1181-1186.
38. CALHOUN WJ, LAVINS BJ, MINKWITZ MC, EVANS R, GEICH GI, COHN J: Effect of zafirlukast (Accolate) on cellular mediators of inflammation: brocnhoalveolar lavage fluid findings after segmental antigen challenge. Am. J. Respir. Crit. Care. Med. (1998) 157:1381-1389.
39. BUSSE W, RAPHAEL GD, GALANT S et al.: Low-dose fluticasone propionate compared with montelukast for first-line treatment of persistent asthma: a randomized controlled trial. Allergy. CLin. Immunol. (2001) 107:461-468.
40. RICCIONI G, BALLONE E, SENSI S et al.: Effectiveness of monteukast versus budesonide on quality of life and bronchial reactivity in subjects with mild-persistent asthma. Int. J. Immunopathol. Pharmacol. (2002) 15:149-155.
41. ROSENTHAL R, LAVINS BJ, HANBY LA: Effect of treatment with zafirlukast (Accolate) on bronchial hyperresponsiveness in patients with mild-to-moderate asthma. J. Allergy. Clin. Immunol. (1997) 97:250-255.
42. RICCIONI G, CASTRONUOV0 M, DE BENEDICTIS M et al.: Zafirlukast versus budesonide on bronchial reactivity in subjects with mild-persistent asthma. Int. J. Immunopathol. Pharmacol. (2001) 14:87-92.
43. LEFF JA, BUSSE WW, PEARLMAN D, BRONSKY EA, KEMP J, HENDELES L: Montelukast, a leukotriene receptor antagonist, for the treatment of mild asthma and exercise-induced bronchoconstriction. N. Engl. J. Med. (1998) 339:147-152.
44. 4 after exercise and attenuation of exercise-induced bronchospasm by montelukast, a cysteinyl leukotriene receptor antagonist. Thorax (1997) 52:1030-1035.
45. MASTALERZ L, GAWLEWICZ-MROCZKA A, NIZANKOWSKA E, CMIEL A, SZCZEKLIK A: Protection against exercise-induced bronchoronstriction by montelukast in aspirin-sensitive and aspirin-tolerant patients with asthma. Clin. Exp. Allergy (2002) 32:1360-1365.
46. REISS TF, CHERVINSKY P, DOCKHORN RJ, SHINGO S, SEIDENBERG B, EDWARDS TB: Montelukast, a once-daily leukotriene-receptor antagonist, in the treatment of chronic asthma. Arch. Intern. Med. (1998) 158:1213-1220.
47. FISH JE, KEMP JP, LOCKEY RF, GLASS M, HANBY LA, BONUCCELLI CM: Zafirlukast for symptomatic mild-to moderate asthma: a 13-week multicenter study. The Zafirlukast Trialist Group. Clin. Ther. (1997) 19:675-690.
48. SUISSA S, DENNIS R, ERNST P, SHEEHY O, WOOD-DAUPHINEE S: Effectiveness of the leukotriene receptor antagonist zafirlukast for mild-to moderate asthma. A randomized, double-blind, placebo-controlled trial. Ann. Intern. Med. (1997) 126:177-183.
49. PRICE DB, HERNANDEZ D, MAGYAR P et al.: Clinical Outcomes with Montelukast as a Partner Agent to Corticosteroid Therapy (COMPACT) International Study Group. Randomised controlled trial of montelukast plus inhaled budesonide versus double dose inhaled budesonide in adult patients with asthma. Thorax (2003) 58:211-216.
50. REISS TF, NGUYEN HH, BRATTON DL: Montelukast, a leukotriene receptor antagonist, for the treatment of persistent asthma in children aged 2 to years. Pediatrics (2001) 108:E48.
51. SINGULAIR TABLETS AND CHEWABLE TABLETS (montelukast sodium): Physician's Desk Reference (53rd Edition) Medical Economics Co, MJ, USA (1999):1886-1889.
52. SPECTOR SL AND ANTILEUKOTRIENE WORKING GROUP: Safety of antileukotriene agents in asthma management. Ann. All. Asthma. Immunol. (2001) 86:18-23.
53. SINGULAIR: Manufacture's prescribing information. Merck and Co, NJ, USA (1999).
54. 4 receptor antagonist. Can. J. Physiol. Pharmacol. (1995) 73:191-195.
55. KANNIESS F, RICHTER K, JANICKI S, SCHLEISS MB, JORRES RA, MAGNUSSEN H: Dose reduction of inhaled corticosteroids under concomitant medication with montelukast in patients with asthma. Eur. Respir. J. (2002) 20:1080-1087.
56. BISGAARD H, NIELSEN KG: Bronchoprotection from leukotriene receptor antagonist in asthmatic pre-school children. Am. J. Respir. Crit. Care. Med. (2000) 162:187-190.
57. MEYER KA, ARDUINO JM, SANTANELLO NC, KNORR BA, BISGAARD H: Response to montelukast among subgroups of children aged 2 to 14 years with asthma. J. Allergy. Clin. Immunol. (2003) 111:757-762.
58. NOONAN MJ, CHERVINSKY P, BRANDONT M et al.: Montelukast, a potent leukotriene receptor antagonist, causes dose-related improvements in chronic asthma. Eur. Respir. J. (1998) 11:1232-1239.
59. MALMSTROM K, RODRIGUEZ-GOMEZ G, GUERRA J et al.: Oral montelukast, inhaled beclometasone, and placebo for chronic asthma. Ann. Intern. Med. (1999) 130:487-495.
60. ALTMAN LC, MUNK Z, SELTZER J et al.: A placebo-controlled, dose-ranging study of montelukast, a cysteinyl leukotriene-receptor antagonist. J. Allergy. Clin. Immunol. (1998) 102:50-56.
61. LAVIOLETTE M, MALMSTROM V, LU S et al.: Montelukast added to inhaled beclometasone in treatment of asthma. Am. J. Respir Crit. Care. Med. (1999) 160:1862-1868.
62. EDELMAN JM, TURPIN JA, BRONSKY EA et al.: Oral montelukast compared with inhaled salmeterol to prevent exercise-induced bronchoconstriction. A randomized, double-blind trial. Exercise Study Group. Ann. Intern. Med. (2000) 132:97-104.
63. RODRIGO GJ, RODRIGO C: Intravenous montelukast in acute asthma. Am. J. Respir. Crit. Care. Med. (2004) 169:130-131.
64. CAMARGO CA Jr, SMITHLINE HA, MALICE MP, GREEN SA, REISS TF: A randomized controlled trial of intravenous montelukast in acute asthma. Am. J. Respir. Crit. Care. Med. (2003) 167:528-533.
65. BAUM D, CREER TL: Medication compliance in children with asthma. J. Asthma. (1986) 23:49-59.
66. CREER TL: Medication compliance and childhood asthma. In: Developmental Aspects of Health Compliance Behavior. NA Krasenger, L Epstein, SB Johnson, SJ Jaffe (Eds), Lawrence Erbaum Associates, Hillsdale, NJ, USA (1999):303-333.
67. JONASSON G, CARLSEN KH, MOWINCKEL P: Asthma drug adherence in a long term clinical trial. Arch. Dis. Child. (2000) 83:330-333.
68. ACCOLATE: Manufacturer's prescribing information. Zeneca Pharmaceuticals, Carolina, Puerto Rico (1999).
69. ADKINS JC, BROGDEN RN: Zafirlukast. A review of its pharmacology and therapeutic potential in the management of asthma. Drugs (1998) 55:121-144.
70. SPECTOR SL, SMITH LJ, GLASS M: Effects of 6-weeks of therapy with oral doses of ICI,219, a leukotriene D4 receptor antagonist, in subjects with bronchial asthma. ACCOLATE Asthma Trialists Group. Am. J. Respir. Crit. Care. Med. (1994) 150:618-623.
71. DUNN CJ, GOA KL: Zafirlukast an update of its pharmacology and therapeutic efficacy in asthma. Drugs (2001) 61:285-315.
72. NATHAN RA, BERNSTEIN JA, BIELORY L et al.: Zafirlukast improves asthma symptoms and quality of life in patients with moderate reversible airflow obstruction. J. Allergy. Clin. Immunol. (1998) 102:935-942.
73. 4-receptor antagonist zafirlukast attenuates exercise-induced bronchoconstriction in children. J. Pediar. (1998) 134:273-276.
74. CROPP GJA: Third international pediatric consensus statement on the management of childhood asthma. Pediatr. Pulmonol. (1998) 25:1-17.
75. KNORR B, FRANCHI LM, BISGAARD H et al.: Zafirlukast improves pulmonary function in patients with moderate persistent asthma receiving regular inhaled steroids: a prospective randomized control study. Chang. Gung. Med. J. (2003) 26:554-560.
76. BRABSON JH, CLIFFORD D, KERWIN E et al.: Efficacy and safety of low-dose fluticasone propionate compared with zafirlukast in patients with persistent asthma. Am. J. Med. (2002) 113:15-21.
77. LAKOMSKI PG, CHITRE M: Evaluation of the utilization patterns of leukotriene modifiers in a large managed care health plan. J. Manag. Care Pharm. (2004) 10:115-121.
78. ACCOLATE (zafirlukast tablets): Physicians' Desk Reference (53rd Edition). Medical Economics Co, Montvale, MJ, USA: (1999) 3402-3404.
79. KEMP JP, KORENBLAT PE, SCHERGER JE, MINKWITZ M: Zafirlukast in clinical practice: results of the Accolate Clinical Experience and Pharmacoepidemiology Trial (ACCEPT) in patients with asthma. J. Fam. Pract. (1999) 48:425-432.
80. KEAM SJ, LYSENG-WILLIAMSON KA, GOA KL: Pranlukast: a review of its use in the management of asthma. Drugs (2003) 63:991-1019.
81. HORIGUCHI T, KONDO R, MIYAZAKI J et al.: Clinical effects of long-term administration of pranlukast, a leukotriene receptor antagonist, on adult patients with bronchial asthma. Nihon Kokyuki Gakkai Zasshi (2003) 41:696-703.
82. TOMARI S, SHIMODA T, KAWANO T et al.: Effects of pranlukast, a cysteinyl leukotriene receptor 1 antagonist, combined with inhaled beclomethasone in patients with moderate or severe asthma. Ann. Allergy Asthma Immunol. (2001) 87:156-161.
83. OBASE Y, SHIMODA T, TOMARI S et al.: Efficacy and safety of long-term treatment of asthmatic patients with pranlukast, a cysteinyl-leukotriene-receptor antagonist: four-year follow-up study. Ann. Allergy Asthma Immunol. (2001) 87:43-47.
84. YOO SH, PARK SH, SONG JS et al.: Representing Korea Pranlukast Study Group. Clinical effects of pranlukast, an oral leukotriene receptor antagonist, in mild-to-moderate asthma: a 4 week randomized multicentre controlled trial. Respirology (2001) 6:15-21.
85. YOSHIDA S, ISHIZAKI Y, SHOJI T et al.: Effect of pranlukast on bronchial inflammation in patients with asthma. Clin. Exp. Allergy (2000) 30:1008-1014.
86. NAKAMURA Y, HOSHINO M, SIM JJ, ISHII K, HOSAKA K, SAKAMOTO T: Effect of the leukotriene receptor antagonist pranlukast on cellular infiltration in the bronchial mucosa of patients with asthma. Thorax (1998) 53:835-841.
87. BARNES NC, PUJET JC: Pranlukast, a novel leukotriene receptor antagonist: results of the first European, placebo controlled, multicentre clinical study in asthma. Thorax (1997) 52:523-527.
88. 4) challenge in normal volunteers. Thorax (1997) 52:519-522.
89. GROSSMAN J, FAIFERMAN I, DUBB JW et al.: Results of the first US double-brind, placebo-controlled, multicenter clinical study in asthma with pranlukast, a novel leukotriene receptor antagonist. J. Asthma. (1997) 34:321-328.
90. YANAGAWA H, SUGITA A, AZUMA M et al.: Long-term follow-up of pulmonary function in bronchial asthma patients treated with pranlukast. Lung (2004) 182:51-58.
91. McGILL KA, BUSSE WW: Zileuton. Lancet (1996) 348:519-524.
92. Zileuton for asthma. Med. Lett. Drugs Ther. (1997) 39(995):18-19.
93. LAZARUS SC, LEE T, KEMP JP: Safety and efficacy of zileuton in patients with chronic asthma. Am. J. Manag. Care. (1998) 4:841-848.
94. LU MC, DUBE LM, LANCASTER J: Acute and chronic effects of a 5-lipoxygenase inhibitor in asthma: a 6-month randomized multicenter trial. Zileutom Study Group. J. Allergy. Clin. Immunol. (1996) 98:859-871.
95. KANE GC, POLLICE M, KIM JC et al.: A controlled trial of the effect of the 5-lypoxygenase inhibitor, zileuton, on lung inflammation produced by segmental antigen challenge in human beings. J. Allergy. Clin. Immunol. (1996) 97:646-654.
96. ISRAEL E, COHN J, DUBE L, DRAZEN JM: Effect of treatment with zileuton, a 5-lypoxygenase inhibitor, in patients with asthma. A randomized controlled trial. Zileuton Clinical Trial Group. JAMA. (1996) 275:931-936.
97. BISGAARD H: Leukotriene modifiers in pediatric asthma management. Pediatrics (2001) 107:381-390.
98. VALACER DJ: New treatments for asthma: the role of leukotriene modifier agents. J. Nath. Med. Assoc. (1999) 91:26S-39S.
99. HERMANSEN CL: Exercise-induced bronchospasm versus exercise-induced asthma. Am. Fam. Physician. (2004) 15:808.
100. ZYFLO FIRMTAB (zileuton tablets): Physician's Desk Reference (53rd Edition). Medical Economics Co, Montvale, MJ, USA (1999) 481-483.
101. SAMPSON AP, CASTLING DP, GREEN CP, PRICE JF: Persistent increase in plasma and urinary leukotrienes after acute asthma. Arch. Dis. Child. (1995) 73:221-225.
102. IGKAWA Y, MIYANOMAE T, INOUE Y et al.: Urinary leukotriene E4 after exercise challenge in children with asthma. J. Allergy. Clin. Immunol. (1992) 89:1111-1119.
103. DAHLEN B, ROQUET A, INMAN MD et al.: Influence of zafirlukast and loratadine on exercise-induced bronchoconstriction. J. Allergy. Clin. Immunol. (2002) 109:789-793.
104. PERONI DG, PIACENTINI GL, PIETROBELLI A et al.: The combination of single-dose montelukast and loratadine on exercise-induced bronchospasin in children. Eur. Respir. J. (2002) 20:104-107.
105. LENNEY W, WELLS NEJ, O'NEILL BA: The burden of paediatric asthma. Eur. Respir. Rev. (1994) 4:49-53.
106. LOFTUS BG, PRICE JF: Clinical and immunological characteristics of preschool asthma. Clin. Exp. Allergy (1986) 16:251-257.
107. STEINSHAMN S, SANDSUND M, SUE-CHU M, BJERMER L: Effects of montelukast on physical performance and exercise economy in adult asthmatics with exercise-induced bronchoconstriction. Scand. J. Med. Sci. Sports. (2002) 12:211-217.
108. BISGAARD H, LOLAND L, ANHOJ J: NO in exhaled air of asthmatic children is reduced by the leukotriene receptor antagonist montelukast. Am. J. Respir. Crit. Care. Med. (1999) 160:1227-1231.
109. BROOKS EG, HAYDEN ML: Exercise-induced asthma. Nurs. Clin. North. Am. (2003) 38:689-696.
110. RICCIONI G, DELLA VECCHIA R, MENNA V, LAMBO MS, DI ILIO C, D'ORAZIO N: The antileukotrienes in the therapy of bronchial asthma. Rec. Prog. Med. (2003) 94:509-515.
111. STORMS WW: Review of exercise-induced asthma. Med. Sci. Sports. Exerc. (2003) 35:1464-1470.
112. SHETH KK: Activity-induced asthma. Pediatr. Clin. North Am. (2003) 50:697-716.
113. KEMP JP, DOCKHORN RJ, SHAPIRO GG et al.: Montelukast once daily inhibits exercise-induced bronchoconstriction in 6-14 year old children with asthma. J. Paediatrics (1998) 133:424-428.
114. VILLARAN C, O'NEILL SJ, HELBLING A et al.: Montelukast versus salmeterol in patients with asthma and exercise-induced bronchoconstriction. J. Allergy. Clin. Immunol. (1999) 104:547-553.
115. ISRAEL E, FISCHER AR, ROSENBERG MA et al.: The pivotal role of 5-lipoxygenase products in the reaction of aspirin-sensitive asthmatics to aspirin. Am. Rev. Respir. Dis. (1993) 148:1447-1451.
116. YAMAMOTO H, NAGATA M, KURAMITSU K et al.: Inhibition of analgesic-induced asthma by leukotriene-receptor antagonist ONO-1078. Am. J. Pespir. Crit. Care. Med. (1994) 150:254-257.
117. MICHELETTO C, TOGNELLA S, VISCONTI M, POMARI C, TREVISAN F, DAL NEGRO RW: Montelukast 10 mg improves nasal function and nasal response to aspirin in ASA-sensitive asthmatics: a controlled study versus placebo. Allergy. (2004) 59:289-294.
118. DAHLEN SE, MALMSTROM K, NIZANKOWSKA E et al.: Improvement of aspirin-intolerant asthma by montelukast, a leukotriene antagonist: a randomized, double-blind, placebo-controlled trial. Am. J. Respir. Crit. Care. Med. (2002) 165:9-14.
119. KEMP JP: Recent advances in the management of asthma using leukotriene modifiers. Am. J. Respir. Med. (2003) 2:139-156.
120. JENKINS C, COSTELLO J, HODGE L: Systematic review of prevalence of aspirin induced asthma and its implications for clinical practice. Br. Med. J. (2004) 328:434-435.
121. SZCZEKLIK A, SANAK M, NIZANKOWSKA-MOGILNICKA E, KIELBASA B: Aspirin intolerance and the cyclooxygenase-leukotriene pathways. Curr. Opin. Pulm. Med. (2004) 10:51-56.
122. MELTZER EO: Role of cysteinyl leukotriene receptor antagonist therapy in asthma and their potential role in allergic rhinitis based on the concept of one linked airway disease. Ann. Allergy Asthma Immunol. (2000) 84:176-185.
123. GROSSMAN J, RATNER PH, MATHEN R, ADELGLASS J, DE JOUNG B: Pranlukast (ultair, SB205312, ONO1078), an oral leukotriene receptor antagonist relieve symptoms in patients with seasonal allergic rhinitis. J. Allergy. Clin. Immunol. (1997) 99:S443.
124. 4 receptor antagonists, ICI204219, relief symptoms of acute seasonal allergic rhinitis. Am. J. Respir. Crit. Care. Med. (1995) 151:1734-1739.
125. NAYAK AS, PHILIP G, LU S, MALICE MP, REISS TF: Montelukast Fall Rhinitis Investigator Group. Efficacy and tolerability of montelukast alone or in combination with loratadine in seasonal allergic rhinitis: a multicenter, randomized, double-blind, placebo-controlled trial performed in the fall. Ann. Allergy. Asthma. Immunol. (2002) 98:592-600.
126. PARNES SM: The role of leukotrienes inhibitors in patients with paranasal sinus syndrome. Curr. Opin. Otolaryngol. Neck. Surg. (2003) 11:184-191.
127. STEINKE JW, BRADLEY D, ARANGO P et al.: Cysteinyl leukotriene expression in chronic hyperplastic sinusitis-nasal polyposis: importance to eosinophilia and asthma. J. Allergy. Clin. Immunol. (2003) 111:342-329.
128. BORISH L: The role of leukotrienes in upper and lower airway inflammation and the implications for treatment. Ann. Allergy. Asthma Immunol. (2002) 88:16-22.
129. ARANGO P, KOUNTAKIS SE: Presence of cysteinyl leukotrienes in asthmatic patients with chronic sinusitis. Laryngoscope (2002) 112:1190-1192.
130. ARANGO P, BORISH L. FRIERSON HF JR, KOUNTAKIS SE: Cysteinyl leukotriene in chronic hyperplastic rhinosinusitis. Otolaryngol. Head. Neck. Surg. (2002) 127:512-515.
131. STEINKE JW, CROUSE CD, BRADLEY D et al.: Characterization of interleukin-4-stimulated nasal polyp fibroblasts. Am. J. Respir. Cell. Mol. Biol. (2004) 30:212-219.
132. HABERAL I, COREY JP: The role of leukotrienes in nasal allergy. Otolaryngol. Head. Neck Surg. (2003) 129:274-279.
133. SCHUBERT MS: Allergic fungal sinusitis: pathogenesis and management strategies. Drugs (2004) 64:363-374.
134. SHEFTELL F, RAPOPORT A, WEEKS R, WALKER B, GAMMERMAN I, BASKIN S: Montelukast in the prophylaxis of migraine: a potential role for leukotriene modifiers. Headache (2000) 40:158-163.
135. ERBAGCI Z: The leukotriene receptor antagonist montelukast in the treatment of chronic idiopathic urticaria: a single-blind, placebo-controlled, crossover clinical study. J. Allergy. Clin. Immunol. (2002) 110-484-488.
136. REIMERS A, PICHLER C, HELBLING A, PICHLER WJ, YAWALKAR N: Zafirlukast has no beneficial effects in the treatment of chronic urticaria. Clin. Exp. Allergy (2002) 32:1763-1768.
137. PACOR ML, DI LORENZO G, CORROCHER R: Efficacy of leukotriene receptor antagonist in chronic urticaria. A double-blind, placebo-controlled comparison of treatment with montelukast and cetirizine in patients with chronic urticaria with intolerance to food additive and/or acetylsalicylic acid. Clin. Exp. Allergy (2001) 31:1607-1614.
138. BAGENSTOSE SE, LEVIN L, BERNSTEIN JA. The addition of zafirlukast to cetirizine improves the treatment of chronic urticaria in patients with positive autologous serum skin test results. J. Allergy. Clin. Immunol. (2004) 113:134-140.
139. RACKAL JM, VENDER RB: The treatment of atopic dermatitis and other dermatoses with leukotriene antagonists. Skin Ther. Lett. (2004) 9:1-5.
140. NETTIS E, PANNOFINO A, FANELLI M, FERRANNINI A, TURSI A: Efficacy and tolerability of montelukast as a therapeutic agent for severe atopic dermatitis in adults. Acta. Derm. Venereol. (2002) 82:297-298.
141. PEI AY, CHAN HH, LEUNG TF: Montelukast in the treatment of children with moderate-to-severe atopic dermatitis: a pilot study. Pediatr. Allergy Immunol. (2001) 12:154-158.
142. YANASE DJ, DAVID-BAJAR K: The leukotriene antagonist montelukast as a therapeutic agent for atopic dermatitis. J. Am. Acad. Dermatol. (2001) 44:89-93.
143. GUILPAIN P, VIALLARD JF, LAGARDE P et al.: Churg-Strauss syndrome in two patients receiving montelukast. Rheumatology (2002) 41:535-539.
144. WECHSLER ME, PAUWELS R, DRAZEN JM: Leukotriene modifiers and Churg-Strauss syndrome: adverse effect or response to corticosteroid withdrawal? Drug Saf. (1999) 21:241-251.
145. NAYAK A: A review of montelukast in the treatment of asthma and allergic rhinitis. Expert Opin. Pharmacother. (2004) 5:679-586.